that's great news, more selling to come from Jack then? This sale was a great success. The only ironic and somewhat humorous thing is Jack cost everyone, even the BOD 10% today. Jack needs a new boat, or a new cottage, everyone pays 10%. Jack has a business savvy impediment.
they would fit nicely with Shire and LLY, or even Abbvie, which has a few CNS assets. Don't see Allergan happening, but they could buy the partnered assets if ACAD is acquired. Those assets + the cash would lighten the risk and cost a little. Still shooting for $40 in a takeover, but would be OK at $35 this year, more if/after approval. Overseas partner deal could add more cash, or they might just take a high sales royalty, or some combo.
Who knows, but IMGN seems to only have one direction, down. The BOD must take action. All shareholders must apply pressure. IMGN sum of parts must be worth at least 50-100% more than the current valuation. I am tired of waiting, Junius needs to go NOW!
He's not CEO material, never has been, he's destroying shareholder value and confidence. Take a seat on the board, go fishing, but hire a business person as President and CEO. This is getting OLD!
Thanks Jack for helping make a new YTD low and heading toward a critical test of $5.5. Shorts will have an easy time covering all they want now thanks to the selfish, non-business savvy, poor communicating CEO. Please retire Jack and find a business person to run the company.
The article paints a negative picture on the prognosis and research. If ACAD can have some success, the path to approval should be rapid and paved with gold.
IMGN officers have done nothing for any of the shareholders, after 25 years the stock has gone no where. Job #1 is to improve shareholder value and the stock price and in that regard they are failing. It's time for the BOD to look at an exit strategy, or replace the failed leader(s). No Bus Dev sonce 2011, no progress in the pipeline for the past year, the list goes on and on.
I am thinking it's Sanofi, we shall see. The negative MS analyst estimated peak sales of the MAb they acquired through IMGN at $1.5BB and they have 2 other molecules. He estimated peak sales for Kadcyla at $6BB+ Then he went on to say IMGN execs will waste all of the money on more failed internal programs.
This morning I sent an email to the new CEO at Takeda suggesting his team take a look. I have been directly contacting IMGN BOD members to voice my displeasure with the current price among other things. IMGN needs to consider/reward their long suffering shareholders.
that depends on whether they were initiated on the bid, or ask, were they open, or close, were they paired with a stock long, or short, or with another option trade... ACAD has been in this price area and failed a few times, hope it can break on through!
I read the full report last night, it's very informative and interesting. It would take all day to present my arguments against the report, it's clearly written for a negative audience, similar to an AF report with more arguments than emotion and hyperbole.
A few interesting take away's are 2H 2014 - 2015 will be exciting and potantially volatile times for IMGN shareholders. We will know by the end of 2015 if IMGN has a valuable ADC platform and technology, or just 5% of 1-3+ successful products. Worst case is the platform does not work and they fire everyone and sell the cash flow and NOL's to Roche and Sanofi.
No credit/value is given to the platform, partnerships, early stage compounds, future milestones. The analyst basically argues, IMGN execs will continue to screw up developing the internal pipeline (based on their track record) and waste all of the cash flow from Kadcyla and the SAR MAb (they only 2 products in which they have confidence or place any value).
It's worth reading for informational purposes. If things go well over the next year, IMGN will have an opportunity to sell for well over $20 and if not, the downside of the cash flows and NOL's should at least be at this valuation. IMGN is low risk with the potential for a double, or triple if the platform or a few of the products work and if the BOD sells the company.
biotech short squeezes are often discussed and hoped-for, rarely happen. Just once in my life I want to be long one with size when it happens like the DNDN's squeeze from about $2 to $40+. ACAD, IMGN, ARNA are all candidates if they get the right kind of good news.
I think they will still get a royalty on sales if the drug is approved, it just depends on how much risk they want to take and how much cost vs. the potential upside. I suggest both companies license it to a larger firm for development, but I don't know anything about Biotest's development capabilities.
POS is falling apart again, I better get back on the phone to the Directors and get them moving, or call Carl...
Don't buy, or fall in love with DSCO, they are a poorly run company, serial losers. Best sale of my life (next to AFFY at $15) was finally giving up and selling 5000 shares at $7.38 before the reverse split. These shares would be almost worthless today. Cooper is a DOPE!
surely this disclosure will jinx the stock, so I sold all of my holdings :-). I have called several Directors and sent an email to another. They never answer, probably click off the voice messages and never return the emails. I guess they like their cozy gig and prefer to avoid any conflict. We all need to turn up the heat. We need a large activist investor to force a sale at $20+.